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Abstract
Background: Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is an essential regulator of glycolysis used as a
housekeeping marker for gene/protein normalisation. Given the pivotal role of GAPDH in tumour metabolism, our
aim was to correlate its protein expression with tumour staging and prognosis of colorectal cancer.
Methods: GAPDH expression was immunohistochemically analysed in tumour tissues from 62 colorectal cancer (CRC)
patients, and validated at mRNA level in an independent dataset comprising 98 paired stage II CRC and normal samples.
Staining quantification was performed by computational image analysis, and correlations between GAPDH expression
and tumour progression stage were assessed. Gene expression profiling was performed using Affymetrix microarrays.
Probability of patient survival and disease-free survival were analysed by the univariate product-limit method of
Kaplan-Meier. Groups were compared using Kruskal-Wallis tests.
Results: Overexpression of GAPDH is positively associated with early stage tumours without regional lymph node and
distant metastases involved. These results were reinforced by those obtained at mRNA level.
Conclusion: Studying the role of GAPDH in malignant transformation can shed new light on the understanding of
tumour onset and lead to the design of more efficient personalised therapies.
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Background
Multifactorial diseases result from the interaction be-
tween genetic susceptibility and environmental factors
and do not exhibit a clear hereditary pattern, which
causes difficulties in their risk evaluation, diagnosis and
treatment. Cancer is a prevalent multifactorial disease
characterised by loss of physiological control and malig-
nant transformation of cells that acquire functional and
genetic abnormalities, leading to tumour development
and progression. In addition, cancer cells from the pri-
mary site can have the ability to invade other tissues
resulting in metastasis, the major cause of death from
cancer.
Colorectal cancer (CRC) is a global leading cause of
cancer-related mortality being the third most common
cancer in men and the second in women worldwide [1].
Fortunately, systematic risk population screening
programmes facilitate early detection and treatment
reducing its incidence and mortality rate. The American
Joint Committee on Cancer (AJCC) TNM staging system
establishes four different stages of tumour progression (I
to IV) depending on the primary tumour extent (T), the
regional lymph node involvement (N) and the absence
or presence of distant metastasis (M) [2]. Cancer staging
systems help oncologists to evaluate disease prognosis,
treatment suitability and the possibilities of patients to
be enrolled in specific clinical trials, contributing to fight
CRC. However, further studies are required to identify
new biomarkers to predict CRC outcome, help to under-
stand its evolution and find the most suitable treatment.
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Glyceraldehyde-3-phosphate dehydrogenase (GAPDH,
EC 1.2.1.12) is an essential regulator of glycolysis ubiqui-
tously overexpressed in 21 cancer classes, being one of
the three glycolytic genes overexpressed in colorectal
cancer, along with enolase and pyruvate kinase [3, 4].
This fact advises against its widely extended use as a
housekeeping gene. GAPDH catalyses the phosphoryl-
ation and oxidation of glyceraldehyde-3-phosphate to
1,3-bisphosphoglycerate coupled with the reduction of
NAD+ to NADH. GAPDH is constituted by four identi-
cal subunits of 37 kDa and has binding sequences for
coenzymes NAD+ and NADH and for nucleic acids. In
fact, GAPDH is one of the multifaceted glycolytic
enzymes that contributes to cell survival and resistance
to cell death [5], becoming a promising biomarker in
cancer research. Moreover, GAPDH expression is reg-
ulated by transcription factors which are frequently
altered in cancer such as HIF-1α, p53 or AP-1. In
addition, GAPDH gene has insulin (IRE) and hypoxia
response elements (HRE) in its promoter [6]. As a
multifunctional enzyme, GAPDH is involved in endo-
cytosis, membrane fusion, vesicle secretion, transcrip-
tion coactivation, cell cycle regulation, tRNA
transport, mRNA stabilisation and DNA repair and
replication [6–8]. Paradoxically, GAPDH also plays
important roles activating apoptosis by nuclear trans-
location upon cellular stress, and protecting from
caspase-independent cell death (CICD) by autophagic
removal of damaged mitochondria [7].
Interestingly, due to its glycolytic role, GAPDH may
also play a part in metabolic reprogramming, one of
the hallmarks of cancer [9] and a suitable target for
cancer therapy as tumour cells require an increased
use of the metabolic pathways to sustain their ener-
getic and biosynthetic needs. Aerobic glycolysis with
high lactate production is one of the main phenotypic
characteristics of tumour metabolism, as described by
Otto Warburg [10]. This phenomenon gives advantage
to cancer cells by an increased production of NADH
and an acidification of the microenvironment due to
lactate excretion, favouring tumour invasion [11].
Glucose metabolism through anaerobic glycolysis is
less efficient in ATP production than oxidative phos-
phorylation. However, the high rate of glucose uptake
and the increased glycolytic flux in cancer cells meet
the requirements for maintaining the energy status,
the biosynthesis of macromolecules and the mainten-
ance of cellular redox balance [12]. Consequently,
GAPDH can be a key enzyme implicated in tumouri-
genesis and cancer progression.
In the current study, we have employed an objective
image analysis quantification method [13] to examine
the expression pattern of GAPDH throughout the stages
of tumour progression in colorectal cancer. In addition,
we have validated our results at mRNA level in an inde-
pendent dataset comprising 98 paired stage II CRC and
normal samples. Correlations between GAPDH expres-
sion and tumour progression are explored in order to
clarify the role of this protein during tumour onset and
development. We have identified significant differences
in GAPDH expression depending on primary tumour
extent, regional lymph node involvement and presence
of distant metastasis.
Methods
Human tissue specimens and patients information
Immunohistochemical samples
This study included 62 non-chosen samples from 45
men and 17 women between 33 and 93 years old (aver-
age 70 ± 11 years old) with CRC which underwent
surgery between November 2000 and October 2001. The
Gastroenterology Department of the Hospital Clínic of
Barcelona recruited all patients as part of the EPICO-
LON project, a prospective multicenter, nation-wide,
population-based study for the establishment of the inci-
dence and characteristics of inherited and familial colo-
rectal cancer forms in Spain [14]. The EPICOLON
project included all newly diagnosed CRC patients in
any participating centre during one-year period. Patho-
logical staging was based on the standard of the AJCC
TNM classification of colon and rectal cancer, which
considers transmural extension, lymph node involve-
ment and presence of metastasis. Our study included
nine tumour samples from stage I patients, 21 from
stage II, 16 from stage III and 16 from stage IV.
After surgery, patients underwent standard thera-
peutic and follow-up measures according to recom-
mended guidelines. Postoperative adjuvant treatment
with 5-fluorouracil and leucovorin was routinely given
to patients with stage II and III tumours, and radi-
ation therapy was indicated in patients with rectal
cancer. Postoperative surveillance consisted of medical
history, physical examination, and laboratory studies
including serum carcinoembryonic antigen (CEA)
levels every three months, abdominal ultrasonography
or computed tomography every six months, and chest
radiograph and total colonoscopy once a year. All
tumour recurrences detected during the follow-up
were histologically confirmed. After a 49-month
period follow-up, 26 patients had died.
Gene expression samples
An independent dataset comprising a set of 98 paired
adjacent-normal and tumour tissues from CRC patients
(196 samples in total) were included in this work (Colo-
nomics project [15], CLX-: www.colonomics.org; NCBI
BioProject PRJNA188510). Patients were selected to
form a homogeneous clinical group of stage II,
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microsatellite stable (MSS) colorectal tumours. All
patients had been treated with radical surgery and had
not received adjuvant therapy. Adjacent normal tissue
from patients was dissected with a minimum proximal
distance of 10 cm from the tumour resection margins.
All patients were recruited at the Bellvitge University
Hospital (Spain) and the Institution’s Ethics Committee
approved the protocol. Written informed consent from
patients was required for inclusion in this study.
Immunohistochemical staining
Tumours were dissected immediately after surgical
resection by a pathologist, snap-frozen and stored in
liquid nitrogen. Tissue specimens (2-5 μm) were
placed on slides and fixed with paraformaldehyde.
Immunohistochemistry was performed as previously
described [13]. Briefly, following heat-induced antigen
retrieval, endogenous peroxidases inhibition and un-
specific staining blockage, slides were incubated with
anti-GAPDH antibody (sc-47724, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA). Negative controls
were incubated with 3% BSA instead of primary anti-
body. After secondary antibody incubation, samples were
treated with streptavidin-peroxidase (Streptavidin-HRP,
LSAB + -kit, DakoCytomation, Hamburg, Germany) and
stained with 3-39-diaminobenzidine (DAB + Chromogen,
Dako- Cytomation, Hamburg, Germany). Slides were
viewed under a LEICA DM4000B microscope (Leica
Microsystems, Germany) and a monochromatic IEEE-
1394 CFW-1312 M camera (Scion Corporation, Frederik,
MD, USA). GAPDH expression was quantified using
ImageJ software (NIH Imaging, USA), measuring relative
intensity per area and interpolating into a calibration
curve plotted using a grey scale. For each sample, 4 to 15
pictures from different areas were quantified. Samples
were processed in groups of eight with representation of
all four stages of tumour progression each time. Values
are presented as relative values in arbitrary units (a.u.).
See Additional file 1: File S1 for detailed methods of im-
munohistochemical staining, total protein extraction and
Western blot analysis.
Gene expression data
RNA extracted from an independent set of 98 paired
adjacent-normal and tumour tissues from CRC patients
(196 samples in total [15]) was hybridised in Affymetrix
chips Human Genome U219. Gene expression profiles of
these samples have been performed as described in [15]
and deposited in the Gene Expression Omnibus (GEO)
database [16] through accession number GSE44076.
Data analysis and statistical methods
Statistical analyses were conducted using Statgraphics
statistical package (Statgraphics Centurion XVI,
StatPoint Technologies Inc., Warrenton, VA). Differ-
ences between two groups were evaluated using the Stu-
dent’s t-test while the analysis of variance (ANOVA) was
employed when comparing more than two groups.
Fisher’s least significant difference (LSD) test was used
to identify which were the groups that specifically
differed from the others. Outliers were identified by
Dixon’s Q-test and homogeneity of variances was
assessed by Levene’s test. Probability of patient survival
and disease-free survival were analysed by the univariate
product-limit method of Kaplan-Meier. All data are
expressed as mean ± standard deviation (SD). Differ-
ences were considered to be significant at P-value <
0.05 (*), P-value < 0.01 (**) and P-value < 0.001 (***).
Results
Patients
GAPDH expression was analysed by immunohisto-
chemistry in 62 patients with primary CRC and con-
firmed not to be age (P = 0.9599) or gender
dependent (P = 0.8091). Table 1 lists demographic,
clinical and tumour-related characteristics. After a 49-
month period follow-up, 26 patients had died.
Immunohistochemical detection of GAPDH expression
Specific and significant labelling was observed in pri-
mary tumours incubated with anti-GAPDH antibody,
while control samples did not present any unspecific la-
belling (Fig. 1). GAPDH antibody was proved to be spe-
cific by Western blot, presenting a single band at 37 kDa
(Additional file 2: Figure S1). The homoscedasticity for
GAPDH expression for all the studied groups was posi-
tively assessed using Levene’s test (P = 0.7046). Having
confirmed the normal distribution of our data applying
the Shapiro-Wilk test, we performed parametric statistic
tests to evaluate the significance of the differences ob-
served. Clinicopathological and immunohistochemical
data are summarised in Additional file 3: Table S1.
GAPDH expression in relation to tumour stage
GAPDH expression ranges from 127.2 to 350.2 a.u.
(mean, 229.0 ± 65.0) in stage I tumours, from 17.0 to
241.3 a.u. (mean, 116.1 ± 70.4) in stage II, from 22.5 to
252.3 a.u. (mean, 125.0 ± 58.9) in stage III and 16.5 to
206.1 a.u. (mean, 92.0 ± 62.2) in stage IV (Fig. 2). These
results showed a significant overexpression of GAPDH
in stage I compared to the other three stages (ANOVA
mean comparison, P = 0.0001). An outlier was identified
(sample 7107, stage IV) using Dixon’s Q-test, presenting
an abnormal high value (317.9 a.u.) compared with the
rest of its group at the 95% confidence level.
Interestingly, GAPDH expression in stage I tumours
was significantly higher than in any other stage of pro-
gression (Fig. 2). In addition, patients who presented
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with a more advanced disease stage (stages II, III and
IV) displayed similar GAPDH expression levels without
any significant differences between them.
GAPDH expression according to primary tumour extent
Considering primary tumour transmural progression
extent, early stage tumours (T1 and T2) presented sig-
nificantly enhanced GAPDH expression values, ranging
from 125.9 to 350.2 a.u. (mean 213.1 ± 68.4; mean
comparison by Student’s t-test, P = 0.00003), compared
to more advanced primary tumour (T3 and T4) which
ranged from 16.5 to 252.3 a.u. (mean 111.3 ± 66.3)
(Fig. 3a). This statement is also applicable when only
considering non-metastatic primary tumours (Fig. 3b).
These data reveal a significant decrease in GAPDH
expression when the depth of invasion into the wall
of the intestine and the extension to adjacent
structures are greater.
GAPDH levels in primary tumours involving regional
lymph nodes
GAPDH expression in patients without regional lymph
node involvement (N0) (mean 147.8 ± 81.6 a.u.) is statis-
tically superior (Student’s t-test, P = 0.0398) than in pa-
tients with metastasis in 1 to 3 (N1) and 4 or more (N2)
regional lymph nodes (mean 106.7 ± 65.2 a.u.) (Fig. 3c).
Influence of distant metastasis in GAPDH expression
Samples from patients who had not developed distant
metastasis (M0) displayed an average value for GAPDH
expression of 141.3 ± 77.7 a.u. while the corresponding
value for those patients who presented with distant me-
tastasis (M1) was 92.0 ± 62.2 a.u. These results depicted
a significant decrease in GAPDH expression (Student’s
t-test, P = 0.0294) in the presence of distant metastasis
(Fig. 3d).
GAPDH expression and survival in colorectal cancer
To assess the relationship between tumour GAPDH
expression, patient survival and disease-free survival
in colorectal cancer, we used univariate Kaplan-Meier
analysis and Mantel-Cox log rank test. We found that
there is no significant association between GAPDH
expression levels and survival in colorectal cancer
(Mantel-Cox log rank test, P = 0.609 considering all
stages of tumour progression and P = 0.773 for stages
I to III without distant metastasis) (Figs. 4a and 4b).
On the other hand, results suggested a not statisti-
cally significant correlation between overexpression of
GAPDH and increased disease-free survival (mean
values 63.11 ± 3.06 and 52.77 ± 3.97 months for pa-
tients with high and lower GAPDH expression levels,
respectively; Mantel-Cox log rank test, P = 0.051
considering all stages of tumour progression and P =
0.064 for stages I to III without distant metastasis)
(Figs. 4c and 4d).
GADPH expression validation in an independent dataset
To further validate differences in GAPDH expres-
sion, an independent dataset comprising 98 normal-
tumour paired samples was used. In this series, gene
expression was evaluated using Affymetrix microar-
rays. As a result, statistically significant differences
Table 1 Demographic, clinical and tumour-related characteris-
tics of patients included in the study (n = 62)
Age (years)a 69.5 ± 11.4
Gender – n° (%) Male 45 (72.6)
Female 17 (27.4)
Family history of colorectal
cancer – n° (%)
10 (16.1)
Fulfillment of revised Bethesda
guidelines – n° (%)
14 (22.6)
Tumour location – n° (%) Proximal to splenic flexure 19 (30.6)
Distal to splenic flexure 43 (69.4)




Tumour size (mm)a 43 ± 20




type – n° (%)
10 (16.1)
Mismatch repair
deficiency – n° (%)b
4 (6.5)
Synchronous colorectal
cancer – n° (%)
5 (8.1)
Synchronous colorectal
adenoma – n° (%)
23 (37.1)
Surgical treatment – n° (%) Right colectomy 16 (25.8)
Left colectomy 6 (9.7)
Sigmoidectomy 22 (35.5)
Anterior resection 9 (14.5)








aExpressed as mean ± standard deviation
bAll four cases correspond to loss of MLH1 protein expression
cAll chemotherapeutic regimens included 5-fluorouracil, five of them in
combination with oxaliplatin and two in combination with irinotecan
dExpressed as median (range)
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in GAPDH expression between normal and tumour
samples were found (P = 2.2 · 10-16). As expected,
tumour samples overexpressed GADPH when com-
pared with the normal ones (Fig. 5). Moreover, the
variability of gene expression is greater in tumour
than in normal samples (log2 expression ranging
from a minimum of 9.8 and a maximum of 13.1). In
addition, in order to compare the expression of
GAPDH in different cancer studies, we consulted the
cBioPortal database (http://www.cbioportal.org/
index.do) [17, 18] and we found a significant disper-
sion of GAPDH expression in the cancer sites avail-
able in the database.
Discussion
In tumour cells, upregulation of aerobic glycolysis
with elevated lactate production generates an acidic
and hypoxic extracellular microenvironment which
Fig. 1 GAPDH expression in colorectal tumours in different stage of progression. a Representative colour photomicrographs presenting
immunohistochemical staining (brown) for GAPDH in colorectal tumours (x200). Stained tissues at different stages of progression are
displayed in the right column and homologous areas in negative controls in the left column. b Representative monochromatic
photomicrographs were analysed with ImageJ software to quantify immunostaining and assess GAPDH expression (x150). Stained tissues
at different stages of progression are portrayed in the right column and homologous areas in negative controls in the left column. For
both (a) and (b), representative photomicrographs used were from sample 7058 for stage I, sample 7020 for stage II, sample 7112 for
stage III and sample 7104 for stage IV
Fig. 2 GAPDH expression in relation to tumour stage. Box and whiskers plot illustrates GAPDH overexpression observed in stage I primary
tumours. Mean values are represented by a cross and median values by a horizontal line in each group
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Fig. 3 Correlation between GAPDH expression and TNM classifications. a GAPDH expression in relation to the primary tumour extent in all 62
patients and (b) in patients who had not developed distant metastasis. In both cases, GAPDH expression is significantly higher in tumours that
have only affected the most external layers of the colonic wall (submucosa and muscularis propria) than in tumours in more invasive stages
(invasion into the subserosa, non-peritonealised pericolic or perirectal tissues, other organs and/or perforation of visceral peritoneum). c The
presence of metastases in regional lymph nodes is correlated with a significant decrease in primary tumour GAPDH expression. d In the absence
of distant metastasis, tumours express significantly higher levels of GAPDH
Fig. 4 Correlation between GAPDH expression and patient survival. a Kaplan-Meier plot correlating GAPDH expression and survival in
patients with colorectal cancer (P = 0.609). b In patients with non-metastatic colorectal cancer (P = 0.773). c Kaplan-Meier plot correlating
GAPDH expression and disease-free survival in patients with colorectal cancer (P = 0.051). d In patients with non-metastatic colorectal
cancer (P = 0.064). Black line represents the group of patients whose GAPDH expression is higher than the median values, and grey line
represents those with GAPDH expression lower than the median values
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gives a selective growth advantage to malignant cells
and facilitates invasion through destruction of
adjacent normal populations, degradation of the extra-
cellular matrix by metalloproteases and promotion of
angiogenesis [19]. Hypoxia and glycolytic products
such as lactate and pyruvate can stimulate hypoxia-
inducible factor 1 (HIF-1α) accumulation in solid tu-
mours leading to upregulation of survival genes, an-
giogenic factors and glycolytic enzymes, including
GAPDH [20–22]. Overexpression of almost every
glycolytic enzyme has been described in prostate and
brain cancers [3]. However, GAPDH, enolase and
pyruvate kinase are the only glycolytic genes whose
expression is enhanced in colorectal cancer. Accord-
ing to our results, GAPDH is increased in all stages
of colorectal tumour progression, reaching its max-
imum in stage I and with a moderate overexpression
in the subsequent stages. These findings suggest that
in addition to its role in glycolysis, GAPDH may be
involved in non-glycolytic processes during tumour
onset. Moreover, overexpression of GAPDH in CRC
tumours has been validated in an independent dataset
comprising 196 paired stage II CRC and normal sam-
ples, which reinforces the significant role of this gene
in tumourigenesis. In fact, GAPDH is known to be a
multifunctional protein implicated not only in glycoly-
sis but also in many other highly relevant non-
glycolytic processes in cells such as the cellular re-
sponse to oxidative stress and DNA damage, tran-
scriptional and post-transcriptional gene regulation,
intracellular membrane trafficking, cell cycle regula-
tion, receptor mediated cell signalling, autophagy and
apoptosis [8]. All these multiple activities interconnect
GAPDH expression and tumourigenesis.
In colon carcinogenesis the selective repression of
mitochondrial β-F1-ATPase expression, which reduces
oxidative phosphorylation, leads to an increase in
GAPDH expression [23] that may explain the rise of
GAPDH levels observed in the initial stages of tumouri-
genesis. Moreover, the reduction of β-F1-ATPase expres-
sion limits electron flux through electron transport
chain, which is the main endogenous source of oxidative
stress, causing the diminution of free radical generation
and the risk of apoptosis. Therefore, this could be a
mechanism by which cells simultaneously acquire high
levels of GAPDH and protect themselves against oxida-
tive stress. Indeed, GAPDH is a redox-sensitive enzyme
whose activity is affected by oxidation of the cysteine
residue located in its catalytic site [24, 25]. The oxida-
tion of GAPDH depends on the intracellular reactive
oxygen species (ROS) concentration. Interestingly, a dual
modulation of GAPDH activity has been described in
cells exposed to sub-apoptogenic and apoptogenic oxida-
tive stress levels. Under mild oxidative stress conditions,
such as the one that is induced by the repression of
mitochondrial β-F1-ATPase, GAPDH is strongly hyper-
activated, while apoptogenic stress levels inhibit GAPDH
activity [26, 27]. In advanced stages of tumour progres-
sion, oxidative stress is higher than in early phases of
carcinogenesis [28–30], which can explain the increased
levels of GAPDH in stage I in comparison with later
stages of progression. In addition, overexpression of
GAPDH has two cooperative roles in protection towards
caspase-independent cell death; a high glycolytic ATP
production and the induction of autophagy-mediated
clearance of damaged mitochondria [6, 7], both of which
favour tumour onset.
On the other hand, under high oxidative stress
conditions, chaperone-mediated autophagy (CMA) is
upregulated in order to selectively remove altered or
damaged proteins. As a CMA putative substrate,
GAPDH contains a KFERQ-like motif that is recog-
nised by chaperone heat shock cognate 70 (Hsc70)
for lysosomal degradation [31]. The abovementioned
increase of oxidative stress in advanced stages of
tumour progression can trigger GAPDH inactivation
and subsequent CMA, resulting in the observed re-
duction of protein expression compared to early
tumour stages.
The capability to sustain proliferative signalling is
one of the hallmarks required in tumourigenesis [9].
GAPDH can enhance cell proliferation during tumour
onset by binding to the SET protein at the same site
of cyclin B and reversing the inhibitory effects of SET
on cyclin B-CDK1 complex [32]. As we mentioned
before, metabolic reprogramming is another hallmark
of cancer that allows tumour cells to fulfil the
increased demands for energy and macromolecules
Fig. 5 GAPDH gene expression. Gene expression levels of GAPDH in
normal and tumour colorectal tissue samples (P = 2.2 · 10-16)
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required to sustain the accelerated proliferation rates
[9]. In fact, glycolysis is a key pathway in the tumour
metabolic reprogramming and a potential target for
cancer therapy [33]. Non-tumour cells are expected
to be less sensitive to glycolysis inhibition than malig-
nant cells, which are more dependent on this pathway to
generate ATP and proliferate [34]. Therefore, GAPDH
emerges as a promising therapeutic target against cancer
since it is overexpressed in 21 cancer classes [3] and in-
volved not only in cell proliferation and glycolysis but also
in several other mechanisms which are upregulated in
tumour cells [35, 36].
Previous studies have correlated GAPDH expression
with an overall poor prognosis. However, in these re-
ports tumour samples were obtained from patients
with advanced stages of tumour progression (II–IV)
[4, 23, 37, 38], without tumour staging classification
[39] or where GAPDH gene but not protein expres-
sion was quantified [40, 41]. In the present study, we
have observed a significant overexpression of GAPDH
protein during the tumour onset which is associated
with patients in the early stages of disease (stage I)
and a better outcome.
Finally, the use of GAPDH as a housekeeping gene
or internal standard for gene/protein level normalisa-
tion is still widespread even though it is well docu-
mented that this use is inappropriate [42]. Our results
further support this conclusion as we have observed
significant differences in GAPDH expression between
stages of colorectal tumour progression as well as
heterogeneity in GAPDH gene expression levels
between samples.
Conclusion
In this study, we found out that GAPDH expression in
colorectal cancer is significantly upregulated during
tumour onset. These results suggest that GAPDH plays an
important role in colorectal tumourigenesis and could be
used as an early detection biomarker. The monitoring of
GAPDH levels in high-risk population may enable
early diagnosis and better recovering rates. The study
of the expression of GAPDH-related proteins can fur-
ther contribute to the knowledge of the mechanisms
underlying tumour onset and to the design of more
efficient and personalised anti-oncogenic therapies.
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